AJR Customized AJR reprints in quantities as low as 100!
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Figures Only
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cho, S.-M.
Right arrow Articles by Lee, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cho, S.-M.
Right arrow Articles by Lee, J. M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
AJR 2002; 179:391-395
© American Roentgen Ray Society

Usefulness of FDG PET for Assessment of Early Recurrent Epithelial Ovarian Cancer

Song-Mee Cho1, Hyun Kwon Ha2, Jae Young Byun1, Jae Mun Lee1, Chan Joo Kim3, Sung Eun Nam-Koong3 and Joon Mo Lee3

1 Department of Radiology, College of Medicine, The Catholic University of Korea, Seocho-Ku, Seoul, South Korea.
2 Department of Radiology, University of Ulsan College of Medicine, Asan Medical Center, 388-1 Poongnap-Dong Songpa-Ku, Seoul, South Korea.
3 Department of Gynecology, College of Medicine, The Catholic University of Korea, 505 Banpo-Dong, Seocho-Ku, Seoul, South Korea.

Received September 25, 2001; accepted after revision February 13, 2002.

 
Address correspondence to J. M. Lee.


Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
OBJECTIVE. The purpose of our study was to evaluate the diagnostic accuracy of FDG positron emission tomography (PET) in comparison with CT in detecting recurrent ovarian carcinoma and its ability to reveal small tumor recurrence.

MATERIALS AND METHODS. We reviewed the records of 31 consecutive patients with pathologically proven epithelial carcinoma who underwent FDG PET 1 month before second-look surgery to assess recurrent tumor. Of these 31 patients, 21 patients also underwent CT 1 month before second-look surgery. The diagnostic accuracies of FDG PET (n = 31), CT (n = 21), and combined FDG PET and CT (n = 21) in detecting recurrent tumor were calculated and compared with each other using the Bennett's test in 21 patients who underwent both imaging studies. Detection rates of individual tumors relative to their sizes were compared between FDG PET and CT using the McNemar test.

RESULTS. The sensitivity, specificity, and accuracy of FDG PET, CT, and combined FDG PET and CT for revealing recurrent ovarian cancer were 45.3%, 99.7%, 91.0%; 54.5%, 99.6%, 91.7%; 58.2%, 99.6%, 92.4%, respectively. We found no statistically significant difference in the diagnostic accuracy of FDG PET, CT, and combined FDG PET and CT ({chi}2 < 5.991). Detection rates of tumor nodules found on CT were significantly greater than those on FDG PET when nodule size was 0.3-0.7 cm (p < 0.05).

CONCLUSION. FDG PET did not improve the overall diagnostic accuracy in detecting recurrent ovarian carcinoma compared with CT. Rather, FDG PET was inferior to CT in its ability to reveal small-tumor recurrence.


Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Recurrence is a major problem for patients with epithelial ovarian cancer. During the early postoperative period, a peritoneal disseminated lesion is the most common form of recurrence. Detection of a small volume of tumor recurrence in patients with epithelial ovarian cancer on preoperative imaging has always been imperative because patients with tumor recurrence with optimal disease found at second-look surgery have a better prognosis than those with suboptimal disease [1,2,3]. Surgical debulking is considered optimal if the diameter of the largest residual tumor is 2 cm or less and suboptimal if the diameter of the largest tumor is more than 2 cm at second-look surgery [1,2,3].

Clinical evaluation with tumor markers or physical examination is of little diagnostic value in the early detection and localization of recurrent ovarian tumor, leading to a reliance on imaging. CT is the most commonly used diagnostic technique before second-look surgery. However, CT is limited in revealing small lesions; even if the lesion is detected, CT cannot confirm the lesion as a tumor recurrence if it is too small. Recently, several reports have evaluated the usefulness of FDG positron emission tomography (PET) in revealing recurrent ovarian carcinoma [4,5,6,7,8,9,10,11]. However, to our knowledge, no reports show the diagnostic value of FDG PET for the detection of small tumor recurrence. The purpose of our study was to evaluate the value of FDG PET for diagnosis of recurrent ovarian carcinoma in comparison with CT and its ability to reveal small tumor recurrence.


Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
We reviewed the records of 31 consecutive patients with surgically and pathologically proven epithelial carcinoma who were treated between January 1996 and March 2000. These patients underwent FDG PET 1 month before undergoing second-look surgery to assess recurrent tumor. Of these 31 patients, 21 patients also underwent CT. The range between CT and second-look surgery, FDG PET and second-look surgery, and CT and FDG PET was 5-30 days (mean, 17 days), 3-20 days (mean, 13 days), and 3-18 days (mean, 5 days), respectively. The patients who underwent CT or FDG PET more than 1 month before second-look surgery were excluded from our study. Patients ranged in age from 17 to 70 years (mean age, 46 years). The pathologic cell types of the 31 epithelial ovarian carcinomas included serous cystadenocarcinoma (n = 17), mucinous cystadenocarcinoma (n = 7), endometrioid carcinoma (n = 3), clear cell carcinoma (n = 2), and undifferentiated or poorly differentiated carcinoma (n = 2). At second-look surgery, the presence or absence of tumor at 15 specific sites was recorded; these sites included abdominal and pelvic lymph nodes, diaphragm, omentum, mesentery, gastric surface, splenic hilum, hepatic surface, serosa of the large and small bowels, paracolic gutter, peritoneum of the anterior abdomen and pelvis, rectal serosa, and vaginal stump. The tumor masses, if present, were excised by debulking surgery, and blinded biopsies were performed at each site even when no apparent gross mass was present.

FDG PET imaging was performed using an ECAT Exact 47 scanner (Siemens, Knoxville, TN) with a slice thickness of 5.1 and a zoom of 1.0 for whole-body coronal, sagittal, and axial images and a slice thickness of 3.5 and a zoom of 1.5 for regional pelvic axial images. Transmission scanning was performed using a germanium-68 rotating rod source during a 20-min acquisition for attenuation correction of regional pelvic images. Patients were injected IV with 370 MBq of FDG. After an uptake period of 45 min, whole-body emission scanning was initiated with six sequential images from the level of the middle auditory canal to the thigh. Emission scanning was then performed during a 30-min acquisition for attenuation-corrected regional pelvic images. Regional pelvic images were acquired as a set of sinograms and were reconstructed by a filtered back-projection method. To limit artifacts, the patients were asked to fast for 12 hr and to drink more than 500 mL of water. All patients received 5 mg of IV furosemide (Lasix; Han dok-Aventis pharma, Seoul, Korea) and were catheterized to reduce bladder activity. In addition, diazepam (10 mg by mouth) (Valium; Roche, Seoul, Korea) was used routinely to reduce FDG uptake in the skeletal muscles. The standardized uptake value was calculated from the amount of injected FDG, the patient's body weight, and the soft-tissue uptake of FDG in the regional images with the attenuation correction.

CT was performed using a Somatom Plus scanner (Siemens, Erlangen, Germany) with an 8- to 10-mm slice thickness and interval. A total of 100 mL of iopromide 62.3% (Ultravist 300; Schering, Berlin, Germany) was injected as a bolus at a rate of 2-3 mL/sec using a mechanical injector. Incremental or helical scanning from the diaphragm to the symphysis began 45 sec after starting the IV injection of contrast medium.

Two radiologists retrospectively interpreted the same CT scans together without the knowledge of histopathologic results or other imaging findings and came to a consensus on the CT findings. If recurrent tumor manifested as a nodule on CT, the size and site of each nodule were evaluated. Miliary peritoneal seeding was considered to be present when peritoneal thickening and contrast enhancement was visualized on CT.

A nuclear medicine specialist retrospectively interpreted the FDG PET scans. This specialist was also unaware of the histopathologic results or other imaging findings. Whole-body coronal, sagittal, axial, and regional axial black-and-white images were viewed on a computer screen. If a hypermetabolic lesion manifested as a nodule on FDG PET, the size and site of each nodule were evaluated. Estimation of lesion size on FDG PET was based on correlation with CT. If the nodule on the attenuation-corrected pelvic image was more than 2 cm in diameter, the standardized uptake value was measured [12]. If the nodule was less than 2 cm in diameter and it was on the outside of the pelvis, semiquantitative and visual analysis were used in the image interpretation for tumor recurrence [13]. On FDG PET, peritoneal seeding was considered present when FDG uptake was prominent on the peritoneal lining and on the surfaces of the solid organs. The presence of tumor recurrence was evaluated on CT and FDG PET using the following three-level confidence score: 0, absent; 1, equivocal; 2, present. On FDG PET, the presence of a hypermetabolic lesion with a standardized uptake value of more than 3 was considered positive for tumor recurrence (score 2), and suspected tumor recurrence with FDG uptake on visual analysis was considered an equivocal lesion (score 1). Scores 1 and 2 were considered positive for tumor recurrence on CT and FDG PET.

The sensitivity, specificity, accuracy, and positive and negative predictive values were evaluated for the 15 specific sites on FDG PET (n = 31), CT (n = 21), and combined FDG PET and CT (n = 21). These were compared with the results of second-look surgery. Furthermore, these diagnostic accuracies were compared with each other using Bennett's test [14] in 21 cases in which both FDG PET and CT were performed.

The detection rate of FDG PET and CT was evaluated for all tumor nodules confirmed at second-look surgery. To calculate the detection rates for a specific tumor size, we included the number of nodules in the denominator that were larger than the tumor size; the number of correctly detected nodules was the nominator. Detection rates of tumors relative to their sizes were calculated and compared between FDG PET and CT using the McNemar test. Tumor sizes measured at second-look surgery and standardized uptake values of nodules of more than 2 cm were also evaluated on FDG PET.


Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Of the 31 patients with epithelial ovarian cancer, 16 patients had recurrent ovarian carcinoma, and findings in 15 patients were negative for tumor recurrence at second-look surgery after first-line therapy. Eight of the 16 patients with recurrent ovarian carcinoma had optimal disease, whereas the remaining eight had suboptimal disease. Twelve of the 16 patients with recurrent ovarian carcinoma had miliary peritoneal seeding (Figs. 1A,1B and 2A,2B,2C).



View larger version (125K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Fig. 1A. —41-year-old woman with recurrent ovarian cancer in pelvis. Contrast-enhanced CT scan obtained at level of hip joint shows two nodular enhancing lesions (arrows) in pelvis, one just above vaginal stump and second in left pelvic peritoneum. Both lesions were missed on CT.

 


View larger version (131K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Fig. 1B. —41-year-old woman with recurrent ovarian cancer in pelvis. Regional axial FDG positron emission tomogram shows two nodular lesions (arrows) in pelvis.

 


View larger version (148K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Fig. 2A. —39-year-old woman with recurrent ovarian cancer in peritoneum. Contrast-enhanced CT scan obtained at level of liver shows smooth linear contrast enhancement (arrows) along hepatic surface.

 


View larger version (133K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Fig. 2B. —39-year-old woman with recurrent ovarian cancer in peritoneum. Contrast-enhanced CT scan obtained at level of mid abdomen shows subtle nodular linear contrast enhancement (arrows) at peritoneum along right paracolic gutter.

 


View larger version (63K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Fig. 2C. —39-year-old woman with recurrent ovarian cancer in peritoneum. Whole-body coronal image of FDG positron emission tomograsm shows strong FDG uptake at hepatic surface (arrows) and peritoneum (arrowheads) along both paracolic gutters. Urine in bladder (B) also shows FDG uptake.

 

The overall lesion-based sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of FDG PET (n = 31), CT (n = 21), and combined FDG PET and CT for revealing recurrent ovarian carcinoma for 15 specific sites were 45.3%, 99.7%, 91.0%, 97.1%, 90.5%; 54.5%, 99.6%, 91.7%, 96.8%, 91.2%; 58.2%, 99.6%, 92.4%, 97.0%, 91.8%, respectively (Table 1). When lesion-based and patient-based diagnostic accuracies were compared among FDG PET, CT, and combined FDG PET and CT in 21 patients who underwent both imaging studies, no statistically significant difference was seen for diagnostic accuracies ({chi}2 < 5.991).


View this table:
[in this window]
[in a new window]

  		TABLE 1 Diagnostic Accuracy of FDG PET and CT for Revealing Recurrent Ovarian Tumor at 15 Specific Sites

 

Fifty-one recurrent tumor nodules were confirmed at second-look surgery. The size of the tumor nodules ranged from 0.3 to 4.0 cm (mean, 1.1 cm). Detection rates of tumor relative to size on FDG PET and CT at 0.3, 0.4, 0.5, 0.6, and 0.7 cm were significantly greater on CT than those for FDG PET (p < 0.05) (Fig. 3). Although statistically insignificant, tumor detection rates for FDG PET were inferior to those on CT between 0.7 and 1.8 cm. The standardized uptake values of FDG from these measurable tumors of more than 2 cm in diameter were 3.7-16.5 (mean, 8.1).



View larger version (8K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Fig. 3. —Graph shows detection rates for specific tumor sizes on FDG positron emission tomography (dotted line) and CT (solid line). To calculate detection rates for specific tumor size, we included all nodules in denominator that were larger than tumor size. Tumor detection rates on CT for tumors of diameters 0.3-, 0.4-, 0.5-, 0.6-, and 0.7- cm significantly exceeded those for FDG PET (p < 0.05).

 


Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
The treatment trends for patients with epithelial ovarian carcinoma include initial surgical staging with aggressive primary cytoreduction followed by multidrug chemotherapy [15]. Second-look surgical reassessment may be performed in patients who have completed a planned course of treatment to document disease remission, restaging, and secondary cytoreduction, as well as to evaluate the response to multidrug chemotherapy. However, this invasive procedure involves the expense and discomfort of major abdominal surgery and results in disruption of the patients' normal activities. Furthermore, recurrent ovarian carcinoma occurs in 20-50% of all patients even after the findings of second-look surgery are negative [16,17,18,19,20]. Another group of researchers documented the overall rate of morbidity at 19% [21]. Problems with second-look surgery have led clinicians to seek other techniques such as peritoneoscopy for monitoring response to therapy [22].

There is a clear need for accurate, noninvasive diagnostic imaging to formulate an optimal therapeutic strategy for patients with residual or recurrent ovarian carcinoma and to monitor tumor response to therapy. Diverse imaging techniques have been used for this purpose. Among the imaging techniques, CT is most often used before second-look surgery. CT has considerable limitations revealing small peritoneal implants, which are the most common presentation of recurrent epithelial ovarian cancer. The overall sensitivity of CT for revealing residual tumor or tumor recurrence is reported to be in the range of 40-61% [23,24,25,26,27,28,29]. In addition, CT cannot definitely confirm tumor recurrence when only small nodular lesions are detected. To overcome these inherent limitations of CT, other diagnostic techniques, such as PET, CT with intraperitoneal administration of contrast material [30, 31], and radioscintigraphy using indium or various tumor markers, are alternative methods [32,33,34].

Several reports have suggested that FDG PET can reveal lesions otherwise missed on CT in recurrent ovarian carcinoma [4,5,6,7,8,9]. FDG PET is a form of computer-assisted imaging that produces images reflecting the biochemistry of tissues rather than their physical characteristics. It has the potential to reveal the biochemical differences between normal and malignant tissues in primary and metastatic malignancies. For these reasons, reassessment with FDG PET before second-look surgery in recurrent ovarian carcinoma is gaining acceptance because of the possibility for tumor confirmation when the conventional imaging findings are inconclusive. However, FDG PET also has limitations in revealing small lesions because the clarity of the technique is hampered by the metabolic activity of the tumor.

In our study, FDG PET did not improve overall diagnostic accuracy in revealing recurrent ovarian carcinoma compared with CT. Although patient-based diagnostic values of FDG PET for revealing recurrent ovarian cancer were comparable to those of other reports [4,5,6,7,8,9], the overall lesion-based diagnostic accuracy of FDG PET was much lower. In addition, FDG PET was inferior to CT in revealing small tumors in patients with recurrent ovarian carcinoma. Although in the report by Karlan et al. [6] the researchers could identify tumors of approximately 1.0 cm in diameter using FDG PET, we found detection rates for the nodules of less than 1.0 cm in diameter to be poor—lower than 50% in our study. As a result, we suggest that FDG PET should not be used as a routine screening technique for the detection of recurrent tumor in patients with recurrent ovarian carcinoma in which disseminating small peritoneal seeding is common. Furthermore, FDG PET cannot be performed in patients with suboptimal disease in detecting tumor foci considering the same detection rates as those of CT for nodules that are more than 1.8 cm in diameter. However, additional analysis of sensitivity, specificity, and accuracy based on the combined FDG PET and CT subset in the 21 patients who had both studies showed a slight improvement in sensitivity without a corresponding decline in specificity. This finding suggests that an appropriate further study would reveal the marginal value of FDG PET in those patients with a negative or equivocal result on CT.

The principal limitation of this study was that the FDG PET technique might have limited the sensitivity of PET in our study. Specifically, because the transmission imaging was performed before the injection of FDG, the potential for patient motion was present. We made every effort to maintain the exact position before and after the FDG injection by marking the position on the patient using an Exact ECAT PET scanner. The use of measured attenuation correction rather than segmented attenuation correction increased the noisiness of the attenuation-corrected images. Also, we used only non—attenuation-corrected images outside the pelvis, which would be considered a limitation by many. Finally, the use of filtered back-projection as the reconstruction method rather than an iterative reconstruction method was another factor limiting the sensitivity of our PET technique. Therefore, further study with a new FDG PET technique might be warranted.

There are well-known problems with FDG PET. This technique is poor in determining the location of a lesion with only faintly revealed anatomic landmarks. To increase spatial resolution and allow localization of the tumor foci, other researchers have used a fusion image with anatomic imaging such as CT [6, 35, 36]. Another recognized problem with FDG PET is the false-positive and false-negative results. We experienced one false-positive result with an infected pseudocyst; other observers also reported false-positive results in patients with recurrent ovarian carcinoma on FDG PET [4, 5, 9]. Such results are unavoidable because FDG uptake is dependent on the metabolic rate of the imaged tissue. We experienced another false-positive result with FDG in the ureter on initial interpretation. Differentiation of physiologic colonic (bowel wall and lumen) and urine activity from tumor uptake of FDG is a difficult task. However, we could differentiate miliary tumor implants from bowel by tracing the physiologic FDG uptake on sequential FDG PET images. This task was not easy. Also, we experienced one false-negative result when FDG PET was performed 11 days after the completion of chemotherapy. The protocol for FDG PET at our institution is to perform the technique at least 3 weeks after the completion of chemotherapy to reduce false-negative results. When this patient underwent FDG PET 10 days later, recurrent tumor was detected.

In conclusion, FDG PET did not improve the overall diagnostic accuracy for detecting recurrent ovarian carcinoma compared with CT. Rather, FDG PET was inferior to CT in its ability to reveal small tumor recurrence.


Acknowledgments
 
We thank Yong Gyu Park for statistical analysis of the study; Dae Keun Lo, Jane Lo, and Shi Jung Lo for assistance with manuscript preparation; and Gi Jeong Cheon and Jung Mi Park for data analysis and interpretation of FDG PET images.


References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Munkarah AR, Hallum AV III, Morris M, et al. Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol Oncol 1997;64:13 -17[Medline]
  2. Hoskins WJ. Epithelial ovarian carcinoma: principles of primary surgery. Gynecol Oncol 1994;55:91 -96[Medline]
  3. Kapp KS, Kapp DS, Poschauko J, et al. The prognostic significance of peritoneal seeding and size of postsurgical residual in patients with stage III epithelial ovarian cancer treated with surgery, chemotherapy, and high-dose radiotherapy. Gynecol Oncol 1999;74:400 -407[Medline]
  4. Hubner KF, McDonald TW, Niethammer JG, Smith GT, Gould HR, Buonocore E. Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-[18F]deoxyglucose (2-[18F]FDG). Gynecol Oncol 1993;51:197 -204[Medline]
  5. Kubik-Huch RA, Dorffler W, von Schulthess GK, et al. Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur Radiol 2000;10:761 -767[Medline]
  6. Karlan BY, Hawkins R, Hoh C, et al. Whole-body positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma. Gynecol Oncol 1993;51:157 -181
  7. Yuan CC, Liu RS, Wang PH, Ng HT, Yeh SH. Whole-body PET with (fluorine-18)-2-deoxyglucose for detecting recurrent ovarian carcinoma: initial report. J Reprod Med 1999;44:775 -778[Medline]
  8. Casey MJ, Gupta NC, Muths CK. Experience with positron emission tomography (PET) scans in patients with ovarian cancer. Gynecol Oncol 1994;53:331 -338[Medline]
  9. Schröder W, Zimny M, Rudlowski U, Büll U, Rath W. The role of 18F-fluoro-deoxyglucose positron emission tomography (18F-FDG PET) in diagnosis of ovarian cancer. Int J Gynecol Cancer 1999;9:117 -122[Medline]
  10. Nakamoto Y, Saga T, Ishimori T, et al. Clinical value of positron emission tomography with FDG for recurrent ovarian cancer. AJR 2001;176:1449 -1454[Abstract/Free Full Text]
  11. Rose PG, Faulhaber P, Miraldi F, Abdul-Karim FW. Positron emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparatomy. Gynecol Oncol 2001;82:17 -21[Medline]
  12. Keyes JW. SUV: standard uptake or silly useless value? J Nucl Med 1995;36:1836 -1839[Free Full Text]
  13. Lowe VJ, Hoffman JM, DeLong DM, et al. Semiquantitative and visual analysis of FDG PET images in pulmonary abnormalities. J Nucl Med 1994;35:1771 -1776[Abstract/Free Full Text]
  14. Bennett BM. On comparisons of sensitivity, specificity and predictive value of a number of diagnostic procedures. Biometrics 1972;28:793 -800[Medline]
  15. Howkins WJ. Surgical staging and cytoreductive surgery of epithelial ovarian cancer. Cancer 1993;71:1534 -1540[Medline]
  16. Podratz KC, Malkasian GD Jr, Wieand HS, et al. Recurrent disease after negative second-look laparotomy in stages III and IV ovarian carcinoma. Gynecol Oncol 1988;29:274 -282[Medline]
  17. Miller DS, Ballon SC, Teng NN, Seifer DB, Soriero OM. A critical reassessment of second-look laparotomy in epithelial ovarian carcinoma. Cancer 1986;57:530 -535[Medline]
  18. Friedman JB, Weiss NS. Second thoughts about second-look laparotomy in advanced ovarian cancer. N Engl J Med 1990;322:1079 -1082[Medline]
  19. Ho AG, Beller U, Speyer JL, Colombo N, Wernz J, Beckman EM. A reassessment of the role of second-look laparotomy in advanced ovarian cancer. J Clin Oncol 1987;5:1316 -1321[Abstract/Free Full Text]
  20. Rubin SC, Hoskins WJ, Hakes TB, Markman M, Cain JM, Lewis JL Jr. Recurrence after negative second-look laparotomy for ovarian cancer: analysis of risk factors. Am J Obstet Gynecol 1988;159:1094 -1098[Medline]
  21. Rubin SC, Lewis JL Jr. Second-look surgery in ovarian carcinoma. Crit Rev Oncol Hematol 1988;8:75 -91[Medline]
  22. Ozols RF, Fisher RI, Anderson T, Makuch R, Young RC. Peritoneoscopy in the management of ovarian cancer. Am J Obstet Gynecol 1981;140:611 -619[Medline]
  23. Goldhirsch A, Triller JK, Greiner R, Dreher E, Davis BW. Computed tomography prior to second-look operation in advanced ovarian cancer. Obstet Gynecol 1983;62:630 -634[Abstract/Free Full Text]
  24. Meyer JI, Kennedy AW, Friedman R, Ayoub A, Zepp RC. Ovarian carcinoma: value of CT in predicting success of debulking surgery. AJR 1995;165:875 -878[Abstract/Free Full Text]
  25. Silverman PM, Osborne M, Dunnick NR, Bandy LC. CT prior to second-look operation in ovarian cancer. AJR 1988;150:829 -832[Abstract/Free Full Text]
  26. Buy JN, Moss AA, Ghossain MA, et al. Peritoneal implants from ovarian tumors: CT findings. Radiology 1988;169:691 -694[Abstract/Free Full Text]
  27. Megibow AJ, Bosniak MA, Ho AG, Beller U, Hulnick DH, Beckman EM. Accuracy of CT in detection of persistent or recurrent ovarian carcinoma: correlation with second-look laparotomy. Radiology 1988;166:341 -345[Abstract/Free Full Text]
  28. Buist MR, Golding RP, Burger CW, et al. Comparative evaluation of diagnostic methods in ovarian carcinoma with emphasis on CT and MRI. Gynecol Oncol 1994;52:191 -198[Medline]
  29. Forstner R, Chen M, Hricak, H. Imaging of ovarian cancer. J Magn Reson Imaging 1995;5:606 -613[Medline]
  30. Nelson RC, Chezmar JL, Hoel MJ, Buck DR, Sugarbaker PH. Peritoneal carcinomatosis: preoperative CT with intraperitoneal contrast material. Radiology 1992;182:133 -138[Abstract/Free Full Text]
  31. Halvorsen RA Jr, Panushka C, Oakley GJ, Letourneau JG, Adcock LL. Intraperitoneal contrast material improves the CT detection of peritoneal metastases. AJR 1991;157:37 -40[Abstract/Free Full Text]
  32. Low RN, Carter WD, Saleh F, Sigeti JS. Ovarian cancer: comparison of findings with perfluorocarbon-enhanced MR imaging, In-111—CYT-103 immunoscintigraphy, and CT. Radiology 1995;195:391 -400[Abstract/Free Full Text]
  33. Bohdiewicz PJ, Scott GC, Juni JE, et al. Indium-111 OncoScint CR/OV and F-18 FDG in colorectal and ovarian carcinoma recurrences: early observations. Clin Nucl Med 1995;20:230 -236[Medline]
  34. Method MW, Serafini AN, Averette HE, Rodriguez M, Penalver MA, Sevin BU. The role of radioimmunoscintigraphy and computed tomography scan prior to reassessment laparotomy of patients with ovarian carcinoma: a preliminary report. Cancer 1996;77:2286 -2293[Medline]
  35. Loats H. CT and SPECT image registration and fusion for spatial localization of metastatic processes using radiolabeled monoclonals. J Nucl Med 1993;34:562 -566[Medline]
  36. Schaffler GJ, Groell R, Schoellnast H, et al. Digital image fusion of CT and PET data sets: clinical value in abdominal/pelvic malignancies. J Comput Assist Tomogr 2000;24:644 -647[Medline]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 RadiologyHome page
D. J. A. Margolis, J. M. Hoffman, R. J. Herfkens, R. B. Jeffrey, A. Quon, and S. S. Gambhir
Molecular Imaging Techniques in Body Imaging
Radiology, November 1, 2007; 245(2): 333 - 356.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
Y. Nakamoto, S. Sakamoto, T. Okada, M. Senda, T. Higashi, T. Saga, and K. Togashi
Clinical Value of Manual Fusion of PET and CT Images in Patients with Suspected Recurrent Colorectal Cancer
Am. J. Roentgenol., January 1, 2007; 188(1): 257 - 267.
[Abstract] [Full Text] [PDF]

Home page
 ImagingHome page
M V Pakkal and M Balogun
Imaging of ovarian cancer
Imaging, August 1, 2006; 18(1): 20 - 27.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
N. Subhas, P. V. Patel, H. K. Pannu, H. A. Jacene, E. K. Fishman, and R. L. Wahl
Imaging of Pelvic Malignancies with In-Line FDG PET-CT: Case Examples and Common Pitfalls of FDG PET
RadioGraphics, July 1, 2005; 25(4): 1031 - 1043.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
S. Sironi, C. Messa, G. Mangili, B. Zangheri, G. Aletti, E. Garavaglia, R. Vigano, M. Picchio, G. Taccagni, A. D. Maschio, et al.
Integrated FDG PET/CT in Patients with Persistent Ovarian Cancer: Correlation with Histologic Findings
Radiology, November 1, 2004; 233(2): 433 - 440.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
H. K. Pannu, R. E. Bristow, C. Cohade, E. K. Fishman, and R. L. Wahl
PET-CT in Recurrent Ovarian Cancer: Initial Observations
RadioGraphics, January 1, 2004; 24(1): 209 - 223.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
P. J. Woodward, K. Hosseinzadeh, and J. S. Saenger
From the Archives of the AFIP: Radiologic Staging of Ovarian Carcinoma with Pathologic Correlation
RadioGraphics, January 1, 2004; 24(1): 225 - 246.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
H. K. Pannu, R. E. Bristow, F. J. Montz, and E. K. Fishman
Multidetector CT of Peritoneal Carcinomatosis from Ovarian Cancer
RadioGraphics, May 1, 2003; 23(3): 687 - 701.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Figures Only
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cho, S.-M.
Right arrow Articles by Lee, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cho, S.-M.
Right arrow Articles by Lee, J. M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS